Advertisement
Advertisement
NATR
Nature's Sunshine Products Inc.
16.38
USDSponsored
-3.96
-19.47%
Aug 07, 15:59 UTC -4
Closed
After-Market
16.34
-0.04
-0.26%
NATR Earnings Reports
Positive Surprise Ratio
NATR beat 13 of 19 last estimates.
68%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$131.86M
/$0.33
Implied change from Q2 26 (Revenue/ EPS)
+12.71%
/+57.14%
Implied change from Q3 25 (Revenue/ EPS)
+2.74%
/-8.33%
Nature's Sunshine Products Inc. earnings per share and revenue
On Aug 06, 2026, NATR reported earnings of 0.21 USD per share (EPS) for Q2 26, missing the estimate of 0.27 USD, resulting in a -23.75% surprise. Revenue reached 116.99 million, compared to an expected 126.18 million, with a -7.28% difference. The market reacted with a -19.47% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of 0.33 USD, with revenue projected to reach 131.86 million USD, implying an increase of 57.14% EPS, and increase of 12.71% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Nature's Sunshine Products Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Nature's Sunshine Products Inc. reported EPS of $0.21, missing estimates by -23.75%, and revenue of $116.99M, -7.28% below expectations.
How did the market react to Nature's Sunshine Products Inc.'s Q2 2026 earnings?
The stock price moved down -19.47%, changed from $20.34 before the earnings release to $16.38 the day after.
When is Nature's Sunshine Products Inc. expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Nature's Sunshine Products Inc.'s next earnings report?
Based on 4
analysts, Nature's Sunshine Products Inc. is expected to report EPS of $0.33 and revenue of $131.86M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement